Martina Cartwright
YOU?
Author Swipe
View article: Clinical Best Practices and Insights Toward Improving Recognition, Diagnosis and Treatment of Primary Axillary Hyperhidrosis (PAH)
Clinical Best Practices and Insights Toward Improving Recognition, Diagnosis and Treatment of Primary Axillary Hyperhidrosis (PAH) Open
Background: Primary axillary hyperhidrosis (PAH) is an underdiagnosed and underreported condition with symptoms beginning before age 25. We conducted a literature review and informal interviews with dermatology healthcare providers (HCPs…
View article: Sofpironium Targets M3 Receptors In Vitro and Shows Early Clinically Meaningful Improvement in Primary Axillary Hyperhidrosis Symptoms
Sofpironium Targets M3 Receptors In Vitro and Shows Early Clinically Meaningful Improvement in Primary Axillary Hyperhidrosis Symptoms Open
Background: Sofpironium gel 12.45%, a first-in-class, topical anticholinergic (Ach) FDA approved for primary axillary hyperhidrosis (PAH) in persons ≥9 years, was retrometabolically designed to optimize efficacy and minimize Ach side effec…
View article: Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants
Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants Open
Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irrita…
View article: Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis
Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis Open
OBJECTIVE: Controlling molluscum contagiosum (MC) infections is critical in atopic dermatitis (AD) management. This post hoc analysis assessed the efficacy and safety of berdazimer gel, 10.3% (topical, antiviral, nitric oxide-releasing med…
View article: The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum
The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum Open
Safety and efficacy of berdazimer gel, 10.3% in Japanese patients were favorable and consistent with previous studies.
View article: Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis
Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis Open
Objective Controlling molluscum contagiosum (MC) infections is critical in atopic dermatitis (AD) management. This post hoc analysis assessed the efficacy and safety of berdazimer gel, 10.3% (topical, antiviral, nitric oxide–releasing medi…
View article: The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology
The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology Open
Molluscum contagiosum (MC) is characterized by skin lesions containing the highly contagious molluscum contagiosum poxvirus (MCV). MCV primarily infects children, with one US Food and Drug Administration (FDA)-approved drug-device treatmen…
View article: Defining clinically meaningful improvement in molluscum contagiosum
Defining clinically meaningful improvement in molluscum contagiosum Open
View article: Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials
Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials Open
Berdazimer gel, 10.3% showed favorable efficacy and safety across subgroups.
View article: Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris Open
Clascoterone cream 1% maintained a favorable safety and efficacy profile for up to 12 months in patients aged ≥ 12 years. Eichenfield LF, Hebert AA, Stein Gold L, et al. Long-term safety and efficacy of twice-daily topical clascoterone cre…
View article: Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris
Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris Open
Patient demographics• A total of 600 patients ≥12 years old enrolled in the extension study; 311 and 289 were originally randomized to treatment with clascoterone and vehicle, respectively, in the Phase 3 studies -The safety population inc…
View article: Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris Open
Clascoterone is efficacious, with a favorable safety profile and low rates of local skin reactions in patients ≥12 years of age with facial acne vulgaris. (Clinicaltrials.gov NCT02608450 and NCT02608476) J Drugs Dermatol. 2023;22(2): doi:1…
View article: A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results
A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results Open
NCT04535531 (registered 2 September, 2020).
View article: Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum
Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum Open
Once-daily berdazimer gel, 10.3% was well-tolerated with minimal systemic absorption. J Drugs Dermatol. 2022;21(10):1104-1110. doi:10.36849/JDD.6938.
View article: Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum
Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum Open
ClinicalTrials.gov Identifier: NCT04535531.
View article: Use of a novel navigable tubular retractor system in 1826 minimally invasive parafascicular surgery (MIPS) cases involving deep-seated brain tumors, hemorrhages and malformations
Use of a novel navigable tubular retractor system in 1826 minimally invasive parafascicular surgery (MIPS) cases involving deep-seated brain tumors, hemorrhages and malformations Open
Objectives: This retrospective, observational experiential study aimed to examine the utility of Minimally Invasive Parfasicular Surgery (MIPS) with Brainpath® and/or Myriad™ in a large, diverse patient cohort and to compare observational …
View article: Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris
Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris Open
A low frequency of TEAEs over 9 months of clascoterone treatment was observed.
View article: Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne Open
ClinicalTrials.gov Identifiers: NCT02608450 and NCT02608476.
View article: Clascoterone topical cream, 1%: A novel, local, selective androgen receptor inhibitor. Results from two phase 3 studies in the female cohort
Clascoterone topical cream, 1%: A novel, local, selective androgen receptor inhibitor. Results from two phase 3 studies in the female cohort Open